Not me. I want to give first right of refusal on a Hot App for Cervix,to our potential partner on Axal,and the same for PSA with Merck. No one gets all of HOT like Amgn stole NEO,no way. If they do that I`m selling my shares. Trust me the company realizes what they have with HOT,and the mistake made letting Amgn steal the NEO for so little upfront,when they gathered so much of profits once it`s an approved therapy. Granted they`re footing the bill,but NEO could`ve also been licensed for many different app`s with many different suitors,instead of letting Amgn steal it. Is Amgn gonna start paying for multiple App`s for NEO? NO way,they`ll do one at a time,and that`s why we needed to keep it,and license it off in many pieces.Now,do you see why I think we need to keep HOT,and license out multiple App`s with it,with multiple partners? If the company needs to sell off something completely,then HER2 should be the candidate there,otherwise start licensing HOT APP`s to others,for different solid tumor types of cancers.